It was a great pleasure hosting the 2020 American Intellectual Property Law Association (AIPLA)Women in IP Virtual Global Networking Event in Buenos Aires! A very inspiring session on leadership, gender and diversity. A great thank you to all the attendees for joining us online this year #WIPNE#AIPLA#WomeninIP
USPTO Pilot Program enables deferred-fee payment related to filing of provisional patent applications that combat COVID-19
The United States Patent and Trademark Office (USPTO) launched a pilot program that allows deferring the payment of filing official fees for provisional patent applications that combat COVID-19, until the filing of a corresponding non-provisional application.
The applicants must agree that the technical subject matter disclosed in their provisional applications will be available to the public on USPTO’s website.
In this way, two objectives are achieved: by disseminating the technology, applicants contribute to the fight against COVID-19 while at the same time protecting their patent rights.
To qualify for the program, the subject matter disclosed in the provisional must concern a product or process related to COVID-19, and such product or process requires Food and Drug Administration (FDA) approval for COVID-19 use.
The program accepts applications as from September 17, 2020, for a duration of 12 months.
The Chambers Latin America 2021 ranking has just been released and we are delighted to be recognized once again as a leading IP firm in Argentina #chamberslatinamerica#chambersandpartners#IP
Very proud to be ranked in @Leaders League 2020 in #iplitigation, #patent prosecution and #trademark prosecution in Argentina. Congratulations to Pedro Berkenwald, Alicia Alvarez Berkenwald, Ernesto Machicote, Federico Ulled and Barbara Porcario! #leadersleague
We are thrilled that BERKEN IP has been recognized in the 2020 IAM_magazine Patent 1000 ranking and that three of our partners are among the World’s Leading Patent Professionals #IAMPatent1000
Amid the COVID-19 sanitary emergency, ANMAT -the Regulatory Authority in Argentina-, has established a new simplified mechanism that enables companies dedicated to the import and/or manufacture of critical medical supplies and diagnostic reagents for in vitro use, to expand their product categories and/or carry out the initial authorization of a company in a simplified manner.
Procedure for expanding production categories
Those companies that already have ANMAT’s authorization for importing and/or manufacturing medical products and wish to increase the safety risk class or add new product categories to their production lines, must request an “expansion of product category without structure modification”. Once the request is approved and proof of initiation of the expansion process is obtained, the product registration process may be initiated with ANMAT.
If adding a new product does not involve increasing the safety risk or expanding product categories (of the categories included in the current Good Manufacturing Practices (GMP) Certificate), the product registration process may be initiated with ANMAT directly.
Procedure for carrying out the initial authorization of a company
Those companies that wish to obtain an initial authorization can request it by submitting a set of relevant documents to ANMAT. Authorizations granted through this mechanism are valid until the last working day of December 2020.
Procedure for expanding production through authorized third parties
Those companies currently left without installed productive capacity may expand it through third parties. Said parties must be authorized by the National Institute of Medical Products and will own the product registries while also being held responsible for their manufacture and commercialization.
For assistance with any of the aforementioned procedures, please contact:
Melisa San Juan Attorney-at-Law Regulatory Affairs & Compliance
We use cookies to customize and enhance your experience on our website and optimize the information we offer you. By clicking “accept” you agree to the use we make of cookies.AcceptCookies policy